HC Wainwright Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $221.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 30.74% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a research note on Thursday, December 12th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Stifel Nicolaus boosted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Citigroup raised their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Stock Up 0.9 %

Shares of Krystal Biotech stock opened at $169.04 on Wednesday. The stock has a market capitalization of $4.86 billion, a P/E ratio of 95.50 and a beta of 0.80. Krystal Biotech has a 12-month low of $107.50 and a 12-month high of $219.34. The company has a 50-day simple moving average of $181.01 and a 200 day simple moving average of $185.37.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.67) earnings per share. On average, equities analysts anticipate that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Trail Advisors LLC bought a new position in Krystal Biotech during the third quarter worth about $1,893,000. Swiss National Bank raised its position in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after purchasing an additional 2,900 shares during the period. Sei Investments Co. grew its position in shares of Krystal Biotech by 18.9% in the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after purchasing an additional 6,363 shares during the period. Shaker Investments LLC OH bought a new stake in Krystal Biotech during the 3rd quarter worth approximately $532,000. Finally, Citigroup Inc. raised its holdings in Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after buying an additional 13,874 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).